Final Research Report
This project's final research report is expected to be available by March 2024.
More to Explore...
Results of this Study Presented at ACC.21, Published in NEJM
People with cardiovascular disease who took aspirin to lower their chances of having a heart attack or stroke experienced similar health benefits, including reduced death and hospitalization, whether they took a high or low dose of the medication, according to findings from this study released in May 2021.
The results were presented at ACC.21, the American College of Cardiology’s 70th Annual Scientific Session, and simultaneously published in the New England Journal of Medicine.
This study is the largest aspirin dosing trial conducted in routine care and clinical settings, and the first randomized controlled trial conducted using PCORnet®, the National Patient-Centered Clinical Research Network. Learn more here and through the Summary of Results (right).
Which Aspirin Dose Is Best to Protect Patients with Heart Disease? Our First PCORnet Study
In this blog post, former PCORI Executive Director Joe Selby, MD, MPH, discusses the Board of Governors' approval of funding for this study and some of the key aspects of its design and goals.
ADAPTABLE: The Aspirin Study
Duke Clinical Research Institute
ADAPTABLE Study Different by Design
Study co-investigator Adrian F. Hernandez, MD, MHS, FAHA, discusses how this study is uniquely designed in comparison with more traditional trials, and how it aims to achieve its goals in an efficient, effective and patient-centered manner.
Results of This Project
Related Journal Citations
The Peer-Review Summary for this project will be posted here soon.
*Matthew Roe, MD, MHS was the original Principal Investigator on the project.
- Has Results